Aclaris Therapeutics (ACRS) Return on Equity: 2017-2025
Historic Return on Equity for Aclaris Therapeutics (ACRS) over the last 8 years, with Sep 2025 value amounting to -1.15%.
- Aclaris Therapeutics' Return on Equity fell 86.00% to -1.15% in Q3 2025 from the same period last year, while for Sep 2025 it was -1.15%, marking a year-over-year decrease of 86.00%. This contributed to the annual value of -0.84% for FY2024, which is 35.00% down from last year.
- Aclaris Therapeutics' Return on Equity amounted to -1.15% in Q3 2025, which was down 14.94% from -1.00% recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' Return on Equity ranged from a high of -0.29% in Q3 2024 and a low of -1.15% during Q3 2025.
- Its 3-year average for Return on Equity is -0.70%, with a median of -0.63% in 2023.
- Its Return on Equity has fluctuated over the past 5 years, first surged by 42bps in 2024, then tumbled by 86bps in 2025.
- Quarterly analysis of 5 years shows Aclaris Therapeutics' Return on Equity stood at -0.43% in 2021, then remained steady at -0.43% in 2022, then dropped by 16bps to -0.59% in 2023, then plummeted by 35bps to -0.94% in 2024, then slumped by 86bps to -1.15% in 2025.
- Its Return on Equity stands at -1.15% for Q3 2025, versus -1.00% for Q2 2025 and -0.89% for Q1 2025.